8-K: Aimei Health Extends Business Combination Deadline, Secures $150,000 Promissory Note

Aimei Health Technology Co., Ltd. has extended its deadline to complete an initial business combination by one month to August 6, 2025, funded by a $150,000 unsecured promissory note issued to its Sponsor and United Hydrogen Group Inc.

Summary

• Aimei Health Technology Co., Ltd. (the Company) has extended the period to consummate its initial business combination from July 6, 2025, to August 6, 2025.
• This extension is the eighth of up to 12 permitted under the Company's Amended and Restated Articles of Association.
• An aggregate of $150,000 (the Extension Payment) was deposited into the Company's trust account for its public shareholders to enable this extension.
• In connection with the Extension, the Company issued an unsecured promissory note for $150,000 (the Promissory Note) on July 6, 2025.
• The Promissory Note was issued to Aimei Health Ltd (the Sponsor) and United Hydrogen Group Inc. (United Hydrogen), with each contributing $75,000.
• The Promissory Note does not bear interest and its principal becomes due and payable upon the consummation of a business combination with United Hydrogen.
• The Payees (Sponsor and United Hydrogen) have the right, but not the obligation, to convert the Promissory Note, in whole or in part, into private units of the Company at a price of $10.00 per unit.
• Each private unit consists of one ordinary share and one right to receive one-fifth (1/5) of one ordinary share of the Company, convertible immediately prior to the consummation of the Business Combination.

Sentiment

Score: 4

Explanation: While the extension provides necessary time, the fact that it is the eighth extension and involves incurring a new financial obligation suggests ongoing challenges in securing a business combination. The potential for dilution from the convertible note also adds a cautious element.

Positives

• The extension provides Aimei Health Technology Co., Ltd. an additional month to complete its initial business combination, preventing immediate liquidation.
• The funding for the extension has been secured through a promissory note, ensuring the company can continue its efforts to find a suitable target.

Negatives

• This is the eighth extension, which may indicate ongoing difficulties in identifying or finalizing a suitable business combination target.
• The issuance of an unsecured promissory note creates a new financial obligation for the Company.
• The note's conversion feature could lead to dilution for existing shareholders if exercised.

Risks

• Failure to consummate a business combination with United Hydrogen Group Inc. or any other qualified target by the new Termination Date of August 6, 2025, could lead to the Company's liquidation.
• The unsecured nature of the promissory note means the Payees' claim is not backed by specific assets.
• The Payees' waiver of claims against the trust account means the note is only repayable from non-trust account funds if the business combination does not occur, potentially limiting repayment options.
• Conversion of the promissory note into private units could dilute the ownership stake of existing ordinary shareholders.

Future Outlook

The Company's immediate future outlook is focused on consummating a business combination with United Hydrogen Group Inc. by the newly extended deadline of August 6, 2025.

Management Comments

• Junheng Xie, Chief Executive Officer and Director, signed the report on behalf of Aimei Health Technology Co., Ltd.

Industry Context

This filing is characteristic of a Special Purpose Acquisition Company (SPAC) seeking to extend its operational timeline to complete a de-SPAC transaction. Such extensions are common in the SPAC market, especially during periods of market volatility or when identifying suitable targets proves challenging. The need for multiple extensions (this being the eighth) can signal a prolonged search or difficulties in finalizing a deal, which is a notable trend in the SPAC industry where many vehicles struggle to complete mergers within their initial timelines.

Comparison to Industry Standards

• The need for an eighth extension for a business combination is on the higher end compared to many SPACs that typically complete their mergers within fewer extensions or their initial timeframe. While extensions are common, a prolonged series of extensions can raise concerns about the viability of the target or the SPAC's ability to close a deal.
• The structure of the promissory note, being unsecured and non-interest bearing, with a conversion option into private units, is a standard mechanism for SPAC sponsors or affiliates to provide extension capital.

Corporate Governance

Related Party Transactions

• An unsecured promissory note for $150,000 was issued to Aimei Health Ltd, which is the Company's Sponsor, and United Hydrogen Group Inc., which is the proposed target for the business combination. Both are considered related parties.

Stakeholder Impact

• Shareholders: Face continued uncertainty regarding the business combination and potential dilution if the promissory note is converted into units.
• Creditors (Aimei Health Ltd and United Hydrogen Group Inc.): Provided funding for the extension and hold an unsecured promissory note with a conversion option into equity.

Next Steps

• Consummate a business combination with United Hydrogen Group Inc. by the new Termination Date of August 6, 2025.

Key Dates

Recommendation

Keywords

Aimei Health Technology, SPAC, business combination, extension, promissory note, United Hydrogen Group, Nasdaq, AFJK, trust account, corporate governance, financial obligation